Lunit to Present AI Study on EGFR Mutation Prediction in NSCLC at AACR 2025 in Collaboration with AstraZeneca

Core Insights - Lunit is set to present a deep learning study on predicting EGFR mutations in non-small cell lung cancer (NSCLC) at the AACR Annual Meeting 2025, showcasing the Lunit SCOPE Genotype Predictor in collaboration with AstraZeneca [1][2] Group 1: Study Details - The study utilizes the largest and most diverse training dataset to date, comprising over 12,000 pathology slides, including more than 4,500 EGFR-mutated and over 7,500 wild-type samples from NSCLC patients across multiple countries [3] - The AI model demonstrated consistent performance across various clinical variables, including specimen types, EGFR mutation subtypes, slide scanners, and scan magnifications, indicating its potential for real-world application [4] Group 2: Industry Impact - The collaboration aims to enhance the efficiency of EGFR mutation testing, which is critical for determining treatment options for NSCLC patients, addressing logistical and resource constraints that have previously limited testing [3][5] - The successful application of AI in this context could enable clinicians to prioritize molecular testing, ensuring timely access to targeted therapies for patients [5] Group 3: Company Background - Lunit, founded in 2013, focuses on AI-powered medical image analytics and biomarker analysis to improve cancer diagnosis and treatment, with its FDA-cleared Lunit INSIGHT suite serving over 4,800 medical institutions globally [7] - The company has a strong presence in the medical community, with clinical studies published in prestigious journals and presented at major global conferences [7]